Receive our newsletter – data, insights and analysis delivered to you
June 4, 2009

Novartis to Develop Typhoid Fever Vaccine

The Novartis Vaccines Institute for Global Health (NVGH) has been awarded a €5.15m grant from the Wellcome Trust to develop a bivalent vaccine for typhoid fever. The €5.15m grant will fund preclinical development and Phase I and II studies for a vaccine that protects against S. Typhi

By cms admin

The Novartis Vaccines Institute for Global Health (NVGH) has been awarded a €5.15m grant from the Wellcome Trust to develop a bivalent vaccine for typhoid fever.

The €5.15m grant will fund preclinical development and Phase I and II studies for a vaccine that protects against S. Typhi and S. Paratyphi A.

Novartis chairman and CEO Dr Daniel Vasella said that the vaccine will ultimately have the potential to eradicate this disease.

“The bivalent vaccine being developed by NVGH will use a novel approach to increase efficacy and address the needs of patients that other vaccines have not,” he said.

The vaccines currently available for S. Typhi do not protect infants and young children. S. Paratyphi A is a growing problem causing 25–50% of all typhoid cases.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU